Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Pharmacokinetics and Safety Assessment of 1st- and 2nd-Generation Zinpentraxin Alfa Drug Products in Healthy Volunteers: A Randomized Crossover Study.
Mai TH, Yadav R, Arjomandi A, Jung C, Meier MM, Donaldson F, Zhao R, Ding HT, Hsu JC, Kamath N, Pan L. Mai TH, et al. Among authors: kamath n. Clin Pharmacol Drug Dev. 2024 Jun;13(6):655-664. doi: 10.1002/cpdd.1403. Epub 2024 Apr 23. Clin Pharmacol Drug Dev. 2024. PMID: 38651245 Clinical Trial.
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study.
Raghu G, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Burgess T, Kamath N, Donaldson F, Richeldi L. Raghu G, et al. Among authors: kamath n. Respir Res. 2022 May 21;23(1):129. doi: 10.1186/s12931-022-02047-0. Respir Res. 2022. PMID: 35597980 Free PMC article. Clinical Trial.
Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.
Richeldi L, Schiffman C, Behr J, Inoue Y, Corte TJ, Cottin V, Jenkins RG, Nathan SD, Raghu G, Walsh SLF, Jayia PK, Kamath N, Martinez FJ. Richeldi L, et al. Among authors: kamath n. Am J Respir Crit Care Med. 2024 May 1;209(9):1132-1140. doi: 10.1164/rccm.202401-0116OC. Am J Respir Crit Care Med. 2024. PMID: 38354066 Free PMC article. Clinical Trial.
Genetic and allelic heterogeneity in 248 Indians with skeletal dysplasia.
Jacob P, Singh S, Bhavani GS, Gowrishankar K, Narayanan DL, Nampoothiri S, Patil SJ, Soni JP, Muranjan M, Kapoor S, Dhingra B, Bhat BV, Bajaj S, Banerjee A, Mamadapur M, Hariharan SV, Kamath N, Shenoy RD, Suri D, Shukla A, Dalal A, Phadke SR, Nishimura G, Mortier G, Shah H, Girisha KM. Jacob P, et al. Among authors: kamath n. Eur J Hum Genet. 2024 Dec 20. doi: 10.1038/s41431-024-01776-8. Online ahead of print. Eur J Hum Genet. 2024. PMID: 39706863
Disparities in kidney care in vulnerable populations: A multinational study from the ISN-GKHA.
Erickson RL, Kamath N, Iyengar A, Ademola A, Esezobor C, Lalji R, Hedin E, Arruebo S, Caskey FJ, Damster S, Donner JA, Jha V, Levin A, Nangaku M, Saad S, Tonelli M, Ye F, Okpechi IG, Bello AK, Johnson DW. Erickson RL, et al. Among authors: kamath n. PLOS Glob Public Health. 2024 Dec 20;4(12):e0004086. doi: 10.1371/journal.pgph.0004086. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39705218 Free PMC article.
PrP turnover in vivo and the time to effect of prion disease therapeutics.
Corridon TL, O'Moore J, Lian Y, Laversenne V, Noble B, Kamath NG, Serack FE, Shaikh AB, Erickson B, Braun C, Lenz K, Howard M, Chan N, Reidenbach AG, Cabin DE, Vallabh SM, Grindeland A, Oberbeck N, Zhao HT, Minikel EV. Corridon TL, et al. Among authors: kamath ng. bioRxiv [Preprint]. 2024 Nov 14:2024.11.12.623215. doi: 10.1101/2024.11.12.623215. bioRxiv. 2024. PMID: 39605733 Free PMC article. Preprint.
165 results